Iwai North America Inc.

541 Taylor Way Suite# 4
 San Carlos, CA 94070
 Phone : (650) 486-1541
Fax : (650) 394-8638
 Open weekdays 9 AM-6 PM (PST)
.........................................................................................................................................................................................................................................................
Matriks Biotek's primary areas of investigation:

- Biological drug testing
- Biotherapeutics and novel markers for diseases
- Inflammation and Immunology
- Obesity, type II diabetes and cardiovascular disease
- Infectious diseases
- Oncology
Matriks Biotek SHIKARI® ELISA Kits
Matriks Biotek® Co. is an innovation oriented company committed to the research and development of biological products and technologies that promote immunological health. In the 9 years since their global release, Matriks' SHIKARI® ELISA kits have come to be used by over 30 pharmaceutical industry leaders across 36 countries. 

The growing use of biologics in pharmaceutical products elicits important questions about the efficacy of such treatments and discrepancies in outcomes between individual patients. Matriks' line of SHIKARI ELISA kits allows researchers to accurately monitor drug levels present in samples and the corresponding immunogenic responses, a key diagnostic tool for explaining the success or failure of these drugs and guiding health professionals towards safer, more effective treatments.

PD-1, PD-L1 and CTLA-4
Anti TNF Alpha Blockers
Anti Cancer Drugs
Osteoporosis
Anti-Filgrastim
Anti-Allergic Drug
About Matriks Biotek​
Reference Literature:
Peer Reviewed Journals:

1 Lombardi S, Bernardoni C, Bertolucci D, et al. Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy. Journal of Autoimmunity and Cell Responses, Volume 4, Article 1, 2017.**

3 Aldrich MB, Velasquez FC, Kwon S, Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis, et al., Arthritis Research & Therapy 19:116, 2017.**

5 Gibellini L, De Biasi S, Bianchini E, et al. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis. Richard Y, ed. PLoS ONE. 11(12), 2016.**

6 Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL,Bibby BM, Uldbjerg N, Connell WR, Rosella O, Grosen A, Brown SJ, Kjeldsen J,Wildt S, Svenningsen L, Sparrow MP, Walsh A, Connor SJ, Radford-Smith G, LawranceIC, Andrews JM, Ellard K, Bell SJ. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology. Jul;151(1):110-9, 2016.**

7 Jonathan GG, Beatriz AÁ, Nazco C GJ, Norberto BL, Fernando GN. Plasma levels of trastuzumab in gastric cancer: Case report. J Oncol Pharm Pract. Sep 23, 2016.**

8 Choi SY, Kang B, Lee JH, Choe YH. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease. Gut Liver. Sep 9 2016.**

9 Chen L., et al., Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus. Frontiers in Plant Science August 2016 | Volume 7 | Article 1156.**

12 Won Jae Song, Ben Kang, So Yoon Choi, and Yon Ho Choe. Adalimumab Treatment in Pediatric-Onset Crohn’s Disease Patients after Infliximab Failure: A Single Center Study. Pediatr Gastroenterol Hepatol Nutr. Jun; 19(2): 116–122, 2016.**

13 Hayashi S, et al., Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. Rheumatol Ther (2016) 3:155–166 **

15 Al-Karkhi M.A., et al., Correlation between Anti-infliximab and Anti-CCP Antibodies Development in Patients with Rheumatoid Arthritis Treated with Infliximab in Baghdad Teaching Hospital. IOSR Journal of Dental and Medical Sciences, Volume 14, Issue 11 Ver. IV (Nov. 2015), PP 95-100.**

16 Kui R, Gál B, Gaál M, Kiss M, Kemény L1, Gyulai R. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis. J Dermatol. Sep;43(9):1018-23, 2016.**

19 Fujita T, Murata Y, Hemmi S, Kajiwara M, Yabuki M, et al. (2015) Persistent Complement Activation is Associated with Insulin Resistance and Chronic Inflammation in Overweight Patients with Type 2 Diabetes with Dyslipidemia. Int J Immunol Immunother 2:007, 2015. **

23 Al-Karkhi M.A., et al., Development of Antibodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis. J Fac Med Baghdad, 57: (241-243), 2015.**

24 Bergen T.V., et al., Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery. Acta Ophthalmologica 2015, 667-678.**

26 Pallagi-Kunstár É. et al., Utility of serum TNF-a, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol. 20(17): (5031-5035), 2014. **

27 Khanna R., et al., Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterology & Hepatology, August (478-489),2014. **

29 Erdemli Ö., et al, In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes.2014. Journal of Biomaterials Application, 29(4):524-42, 2014. **

33 Gutierrez A, et al, Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn’s disease, Gut 0:1–9, 2013. **

34 Grosen A., et al, Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease, J Crohns Colitis 2013. **

36 Cheong C, et al, Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF-α Contents and by Stimulating Newly Formed Neurogenesis, Mediators of Inflammation, 2013; Volume 2013, Article ID 620837, 9 pages **http://dx.doi.org/10.1155/2013/620837

38 Bortlik M, et al, Infliximab trough levelsmay predict sustained response to infliximab in patients with Crohn's disease, Journal of Crohn's and Colitis 2012. **

39 Malickova K, et al, Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases, Autoimmun Highlights, 2012. **

40 Takahashi H, et al, Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, Journal of Dermatology 2012; 39: 1- 4. **

41 Seok Lee Y, et al, “Efficacy of Early Infliximab Treatment for Pediatric Crohn’s Disease: A Three-year Follow-up”, Pediatric Gastroenterology, Hepatology & Nutrition 2012; 15(4):243-249 **

Patents:

Controled drug delivery systems for anti-TNF-α WO 2014046631 A1

Preparing method and medical application of optimized plant source recombination humanized bevacizumab

Genetically modified micro-organ secreting antibody and methods of use



PhD Theses:

"Evaluation of Transscleral Permeability Effects of Nanotechnology Based Drug Delivery System in Ocular Drug Applications" 
By Dr. NAGİHAN UĞURLU, Hacettepe University
(In Turkish with English abstract.)

"​Investigation of the Pathomechanism of Diarrhoea-Related Diseases"
By Dr. ÉVA PALLAGI, University of Szeged
(In English)
.....................................................
** Open Access 
.....................................................